Abeona Therapeutics, Inc. (NASDAQ: ABEO) develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead programs are adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA) in collaboration with patient advocate groups, researchers and clinicians. The company is also developing gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder. In addition, Abeona is also developing rare plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using its proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit the company’s website at www.abeonatherapeutics.com